Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9486-9496

  Li, Cheng Zhong ^a   Hu, Jing Jing ^a   Xue, Jian Ya ^a   Yin, Wei ^a   Liu, Ya Yun ^a   Fan, Wen Han ^a   Xu, Hao ^a   Liang, Xue Song ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD4+ CD25+ FoxP3+ T regulatory cells; Chronic hepatitis B; Immune modulation; Nucleoside analogues; Programmed death 1

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; LAMIVUDINE; TELBIVUDINE; TRANSCRIPTION FACTOR FOXP3; VIRUS DNA; ANTIVIRUS AGENT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; THYMIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HOST; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; CHINA; COMPARATIVE STUDY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS B, CHRONIC; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; MIDDLE AGED; REGULATORY T LYMPHOCYTE; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CHINA; CYTOKINES; DNA, VIRAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPACIVIRUS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; LAMIVUDINE; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; THYMIDINE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84908886224     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9486     Document Type: Article

References (28)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
3. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Cretton-Scott E, Schinazi RF, Myers M, Bryant ML, Sommadossi JP. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001; 12 Suppl 1: 119-129 [PMID: 11594678]
4. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378]
5. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454 [PMID: 18080339 DOI: 10.1002/hep.22075]
6. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]
7. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55: 2727-2734 [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4]
8. Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31: 676-684 [PMID: 21457439 DOI: 10.1111/j.1478-3231.2011.02490.x]
9. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975 [PMID: 9727065 DOI: 10.1172/JCI3731]
10. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971 [PMID: 11283861 DOI: 10.1053/jhep.2001.23045]
11. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother 2008; 52: 312-320 [PMID: 17984230 DOI: 10.1128/AAC.00467-07]
12. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ, Huang JH. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123 [PMID: 18803883 DOI: 10.1186/1471-2334-8-123]
13. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769 [PMID: 18697210 DOI: 10.1002/hep.22419]
14. Wu ZG, Yan WM, Guo W, Chen T, Zou Y, Wang HW, Wang XJ, Yang XJ, Lu YL, Luo XP, Ning Q. Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis. J Viral Hepat 2010; 17 Suppl 1: 24-33 [PMID: 20586931 DOI: 10.1111/j.1365-2893.2010.01268.x]
15. Shi TD, Zhang JM, Wang XF, Chen M, Sun H, Chen CB, Ren H. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med 2012; 12: 105-113 [PMID: 21748522 DOI: 10.1007/s10238-011-0151-8]
16. Jiang X, Zhang M, Lai Q, Huang X, Li Y, Sun J, Abbott WG, Ma S, Hou J. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. PLoS One 2011; 6: e28871 [PMID: 22194934 DOI: 10.1371/journal. pone.0028871]
17. Xu J. Quantitative detection of serum HBeAg levels using Paul-Ehrlich international (PEI) reference standard on the Architect platform. Hepatol Int 2012; 6: 7-10
18. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76 [PMID: 12477811 DOI: 10.1128/jvi.77.1.68-76.2003]
19. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719 [PMID: 15140968 DOI: 10.1128/JVI.78.11.5707-5719.2004]
20. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778 [PMID: 15791617 DOI: 10.1002/hep.20649]
21. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-747 [PMID: 16785573]
22. Liang XS, Zhou Y, Li CZ, Wan MB. Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells. World J Gastroenterol 2010; 16: 618-624 [PMID: 20128032 DOI: 10.3748/wjg. v16.i5.618]
23. Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, Chen Z. Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin Immunol 2011; 31: 195-204 [PMID: 21120686 DOI: 10.1007/s10875-010-9483-5]
24. Ye P, Weng ZH, Zhang SL, Zhang JA, Zhao L, Dong JH, Jie SH, Pang R, Wei RH. Programmed death-1 expression is associated with the disease status in hepatitis B virus infection. World J Gastroenterol 2008; 14: 4551-4557 [PMID: 18680238 DOI: 10.3748/wjg.14.4551]
25. Nan XP, Zhang Y, Yu HT, Sun RL, Peng MJ, Li Y, Su WJ, Lian JQ, Wang JP, Bai XF. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol 2012; 25: 21-28 [PMID: 22233255 DOI: 10.1089/vim.2011.0049]
26. + T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm 2012; 2012: 789859 [PMID: 22570512 DOI: 10.1155/2012/789859]
27. Trehan Pati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol 2011; 31: 509-520 [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7]
28. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816 [PMID: 12606735 DOI: 10.1056/NEJMoa020681]